Swiss Semiconductors Stock News

Temenos (SWX:TEMN) is back in focus after a recent share price move that left the stock down about 8% over the past month while still showing a positive total return over the past year. The recent pullback leaves Temenos trading at CHF67.4, with a 30 day share price return that is down 7.8%, a 1 year total shareholder return of 5.6%, and a 3 year total shareholder return of 10.2%. This suggests that momentum has cooled rather than vanished. Compare Temenos's recent pullback with other hand...

Aevis Victoria stock closed at CHF15.80 after a strong run in recent weeks, yet the real story sits in the gap between that price and the portfolio value sitting underneath it. Book value per share, measured as net asset value, is CHF26.75, which leaves the equity trading at more than a 50% discount to what the underlying hospitals, hotels and ventures are marked at. H1 2026 earnings did not blow the doors off on profit, but they reinforced that net asset value is edging higher while...

Adecco Group (SWX:ADEN) is rolling out Agentforce Coworker, Salesforce's Claude powered AI assistant, to 27,000 staff across more than 40 countries following pilot programs in the UK and France. Recent trading has reflected increasing interest in Adecco Group, with the share price at CHF24.46 and a 90-day share price return of 60.5% in addition to a 1-year total shareholder return of 23.34%, even though the 3 and 5-year total shareholder returns remain in decline. Scan how Adecco Group’s AI...

Novartis (SWX:NOVN) agreed to acquire full global rights to Sironax's brain delivery platform for $125 million upfront. The platform is designed to help transport therapies across the blood brain barrier for neurological and rare brain disorders. Sironax keeps certain rights to develop its own pipeline on the technology while Novartis gains broad access to the core platform. Novartis securing Sironax's brain delivery platform matters, but investors should weigh it alongside other factors for...

Helvetia Baloise Holding came into today quietly ahead of the pack. The stock had already logged gains of about 7.6% over the past week and roughly 8.6% over three months, so expectations were not low. The headline from this earnings season is not the share price move. It is the strain between a very rich trailing P/E of 40.9x and a story built on future earnings power rather than current cash flow. Management highlights high forecast profit growth and an ambitious dividend roadmap. Investors...

Sandoz Group issued a €500 million bond with a 4.835% coupon and 12-year maturity, aiming to use the proceeds for general corporate purposes including refinancing existing debt and keeping its average interest rate on gross borrowings below 4%. The new bond extends Sandoz Group’s debt maturity profile to 2038 and supports its goal of preserving investment grade ratings from Moody’s and S&P, which can influence funding flexibility for ongoing biosimilar manufacturing investments. We will now...

Sensirion Holding has launched the DynamiQ-X BG2300 micro-gas chromatograph for biogas upgrading plants and biomethane facilities, providing full gas composition and hydrogen sulfide analysis in about 45 seconds with an inert sample path and standardized configuration. The DynamiQ-X BG2300 targets online process control for biogas and biomethane with worldwide certifications and a single analyzer that delivers calorific value, gas mix and hydrogen sulfide data. This development aligns with...

Nestlé joined five other fast-moving consumer goods companies as a founding member of the Ellen MacArthur Foundation’s PaperFlex Consortium, which focuses on developing recyclable and biodegradable paper-based alternatives to flexible plastic packaging in markets where collection and recycling systems for plastics are limited. The move pushes Nestlé deeper into packaging redesign, which can affect material costs, product shelf life, and route-to-market economics in small-format consumer...

The market liked what it saw. MCH Group closed at CHF6.48 on 17 September, capping a 7-day gain of about 4.2% and a 3‑month climb of roughly 15.7%. The headline story behind that move is earnings quality, not just earnings size. On paper the exhibition operator now runs with a trailing net profit margin of 4.8%, compared with just 0.7% a year earlier, and a P/E of 10.8x that sits below the wider Swiss market. Yet a CHF12.2m one‑off gain sits inside those profits, so anyone looking beyond the...

Bossard Holding (SWX:BOSN) has scheduled a future finance reshuffle, with long-serving CFO Stephan Zehnder set to hand the reins to incoming executive Andreas Jaeger in early 2027. The incoming CFO announcement has arrived at a time when Bossard Holding’s share price has been strong, with a 1-day share price return of 3.02%, adding to a 90-day gain of 20.10% and a year-to-date share price return of 53.21% at a current level of CHF239.0. Scan how Bossard Holding compares with other industrial...

ABB (SWX:ABBN) is back in focus after two fresh product announcements that push deeper into digital infrastructure. The group is pairing Samsung’s SmartThings Pro with ABB Ability Building Pro, and it is rolling out its AquaMaster+ water management platform in India. The fresh product news comes after a choppy few months for ABB’s shares. The 90 day share price return is down 8.7% and the 30 day move is modestly weaker. However, the year to date share price return of 29.85% and a 1 year total...

Aevis Victoria reported half year 2026 results with sales of CHF 639.1 million, revenue of CHF 547.02 million and net income of CHF 5.42 million, with basic and diluted EPS from continuing operations at CHF 0.06. The small uplift in net profit and earnings per share, alongside largely flat revenue, highlights cost control and business mix rather than pure top line expansion as the near term focus for Aevis Victoria. The focus now turns to how Aevis Victoria's investment narrative...

Galderma Group (SWX:GALD) just reported positive topline data from a 162-patient Restylane Volyme study in China for temple hollowing, meeting its primary endpoint and signaling progress in a key aesthetics market. Against that clinical milestone, Galderma Group’s 1-day share price return of 0.49% to CHF154.05 sits alongside a 30-day share price decline of 8.95% and a 90-day share price decline of 10.75%. The 1-year total shareholder return of 6.33% points to modest longer-term gains and...

Helvetia Baloise Holding reported half year 2026 net income of CHF 68.6 million, with basic and diluted EPS from continuing operations at CHF 0.66, compared with CHF 307.2 million and CHF 5.75 a year earlier. The sharp drop in profitability highlights pressure on Helvetia Baloise Holding's earnings power. This is important for funding growth plans and absorbing insurance claims volatility. We will now see how Helvetia Baloise Holding's investment narrative compares with this steep fall in...

Today is shaping up negative for Jungfraubahn Holding AG ( VTX:JFN ) shareholders, with the analysts delivering a...

R&S Group Holding heads into this earnings season with a bruised chart and a flattering mirror. The share price closed at CHF17.96 on 16 September, with the stock down roughly 10% over the past month and about one third over three months, while the valuation still sits on a P/E of 12.9x against much richer peers. The emotional gap hinges on one thing. Profitability is under more pressure, with trailing net profit margin at 13.4% compared with last year’s 15.3%. That margin squeeze is what the...

Stockholm Office Opening Puts Nordic Expansion In Focus Partners Group Holding (SWX:PGHN) is expanding in the Nordics after opening a Stockholm office that will host dedicated investment professionals and support infrastructure, real estate, and private credit activity across the region. For investors watching Partners Group Holding, the new Stockholm office arrives after a tough run. The share price is down 13.68% over 30 days and the year-to-date share price return has fallen 39.86%, while...

Holcim (SWX:HOLN) has launched the Czech Republic's first calcined clay production line to supply its low-carbon ECOPlanet cement range. The new facility is designed to use calcined clay as a partial clinker substitute, aiming to lower the carbon intensity of cement. Management positions this Czech project as part of Holcim's broader push to scale low-carbon building materials across key European markets. Holcim's launch of a Czech calcined clay line for ECOPlanet cement is worth weighing...

In September 2026, European markets have been navigating a complex landscape marked by rising inflation concerns and increased geopolitical tensions, which have driven oil prices higher and put upward pressure on government bond yields. Amidst these challenges, identifying growth companies with high insider ownership can be appealing to investors seeking resilience and alignment of interests in volatile times.

Cash is suddenly interesting again. Short term rates are higher, central banks are tapping the brakes more carefully, and market swings are pushing more money into brokers, custodians, and money market platforms that sit closest to idle cash. That shift can reshape revenue streams and reprice risk. This article walks through three stocks from our Global Cash and Money-Market Platform Beneficiaries screener that appear well positioned for this new focus on cash. The stocks below are just a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Amrize (SWX:AMRZ) has been in focus after the board moved Mario Gross into the role of President, Building Envelope, following Jake Gosa’s resignation. This change places leadership of a core division under new oversight. That leadership reshuffle comes as Amrize trades at CHF32.07, with the share price down 15.3% over the past month and 28.5% over the last quarter, while the 1-year total shareholder return has declined 23.4%, a pattern that points to fading momentum as investors reassess...

Novartis reported Phase III REMODEL-1/-2 data showing that remibrutinib reduced annualized relapse rates and MRI lesions versus teriflunomide in adults with relapsing multiple sclerosis, with a favorable safety profile and plans to seek global regulatory approval. The remibrutinib readout adds another late-stage asset alongside existing priority brands and reinforces Novartis' focus on high-value immunology and neuroscience therapies that can support its broader push for higher quality...

Medacta Group reported half year 2026 sales of €368.17 million and net income of €41.86 million, while also issuing full year guidance targeting 10% to 14% revenue growth in constant currency. The mix of higher sales and lower earnings, combined with explicit revenue growth targets, highlights how Medacta Group is balancing expansion with profitability pressures. We will now assess how Medacta Group's investment narrative could shift in light of its new 10% to 14% constant currency revenue...